- Immune cells use hunger hormones to help heal skin infections and wounds
- New mRNA cancer vaccine designed to target lymph nodes for stronger immune response
- HIV infection may shorten a person’s life expectancy by about 5 years
- Moderna CEO: The COVID-19 vaccine will be updated every year like the iPhone 1 dose per year
- UK approved the world’s first vaccine for COVID-19 Omicron
- New DNA Repair Approach Successfully Repairs Pathogenic Gene Mutations in Patients’ Kidney Cells
New COVID-19 vaccine: Spike protein-ferritin nanoparticle vaccine
- A highly infectious disease that has been extinct for more than 40 years has appeared in New York
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Omicron new variant BA.2.75 has stronger infectivity than BA.4 and BA.5?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
New COVID-19 vaccine: Spike protein-ferritin nanoparticle vaccine. Spike protein-ferritin nanoparticle vaccine is expected to resist a series of coronaviruses including SARS-CoV-2.
A series of pre-clinical studies recently published that the spike protein – ferritin nano- particles (Spike Ferritin Nanoparticle, SpFN) COVID -19 vaccine developed by U.S Walter – Reed Army Institute of Research (WRAIR) can cause not only an effective immune Response, and may also provide extensive protection against the worrying SARS-CoV-2 variants and other coronaviruses.
These researchers developed a SpFN nanoparticle vaccine based on the ferritin platform as part of a forward-looking “pan-SARS” strategy, which aims to respond to the current pandemic and serve as the first line of defense. Prevent the worrying SARS-CoV-2 variants and similar viruses that may appear in the future.
Dr. Kayvon Modjarrad, Director of the Division of Emerging Infectious Diseases of WRAIR and co-inventor of the vaccine, said, “In the past 20 years, the accelerated emergence of human coronaviruses and the rise of SARS-CoV-2 variants, including the most recent Omicron, have highlighted There is a continuing need for the next generation of preemptive vaccines that can provide extensive protection against coronavirus diseases.Our strategy is to develop a’pan-coronavirus’ vaccine technology, which has the potential to protect against multiple coronavirus strains and Species provide safe, effective and lasting protection.”
A preclinical study published in the journal Science Translational Medicine showed that SpFN vaccine can protect non-human primates from diseases caused by the original strain of SARS-CoV-2 and induce a major SARS-CoV-2 mutation.
The high efficiency of the body (including the SARS-CoV-1 virus that appeared in 2002) and a wide range of neutralizing antibody responses.
SpFN entered the first phase of human clinical trials in April 2021 .
The early analysis, which is expected to end in December 2021, will provide new insights into the effectiveness and breadth of SpFN, as demonstrated in preclinical trials, whether its protective effects can be extended to humans.
The data will also allow scientists to compare SpFN immunity with other COVID-19 vaccines that have been approved for emergency use.
Modjarrad said, “This vaccine stands out in the field of COVID-
19 vaccines. The repetitive and orderly display of this coronavirus spike protein on the surface of multifaceted nanoparticles may stimulate immunity, which translates into significantly broader protection. .”
WRAIR has developed a second vaccine candidate, the SARS-CoV-2 Spike (SARS-CoV-2 Spike) receptor-binding domain-ferritin nanoparticle (Receptor-Binding Domain Ferritin Nanoparticle, RFN) vaccine.
For the SpFN vaccine, it targets a smaller part of the coronavirus spike protein. A recent study published in the journal PNAS showed that the RFN vaccine may provide similar protection against a series of SARS-CoV-2 variants and SARS-CoV-1.
Dr. Gordon Joyce, WRAIR structural biologist and vaccine co-inventor, said, “RFN vaccine candidates are more compact and have some natural advantages. Because we are trying to use a single vaccine platform to improve the immune response to multiple coronaviruses, it is still It is considered as part of our pan-coronavirus vaccine development pipeline.”
Dr. Nelson Michael, Director of the WRAIR Infectious Disease Research Center, said, “As COVID-19 evolves, its threat will continue, and eventually there will be other emerging disease threats. Our investment in the development of next-generation vaccines is ahead of COVID-19. -19 and an important step in the future threat of disease.”
About SpFN vaccine developed by WRAIR
The SpFN vaccine is a protein subunit nanoparticle vaccine platform, which means that it shows a fragment of the virus to the immune system to cause a protective response.
SpFN contains multiple coronavirus spike proteins that are attached to the surface of a polyhedral ferritin nanoparticle.
These researchers speculate that presenting multiple copies of the spike protein in an orderly manner may be the key to inducing an effective and extensive immune response.
The platform also has advantages as a potential global vaccine because it remains stable over a wide temperature range. This is particularly useful in environments where ultra-low temperature refrigerators are lacking.
The SpFN vaccine is formulated with an adjuvant called ALFQ. ALFQ is one of the adjuvants in the Army liposome formulation series developed by WRAIR Army researchers.
Adjuvants are a component of vaccines that help activate the immune system and improve the immune response.
Both preclinical studies and early clinical studies have shown that ALFQ is safe and potent as a vaccine adjuvant.
M. Gordon Joyce et al. A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates . Science Translational Medicine, 2021, doi:10.1126/scitranslmed.abi5735.
Hannah AD King et al. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques . PNAS, 2021, doi:10.1073/pnas.2106433118.
Joshua M. Carmen et al. SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses . npj Vaccines, 2021, doi:10.1038/s41541-021-00414-4.
Kathryn McGuckin Wuertz et al. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge .npj Vaccines, 2021, doi:10.1038/s41541-021-00392-7.
M. Gordon Joyce et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity . Cell Reports, 2021, doi:10.1016/j.celrep.2021.110143.
SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults
New COVID-19 vaccine: Spike protein-ferritin nanoparticle vaccine
(source:internet, reference only)